B
BUX
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, BUX has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +145% compared to the S&P TSX Composite Index (Canada)'s +27% growth.
Stocks Performance
BUX vs S&P TSX Composite Index (Canada)
Performance Gap
BUX vs S&P TSX Composite Index (Canada)
Performance By Year
BUX vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BioMark Diagnostics Inc
Glance View
BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.
